iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...
Business Insider16d
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024 taking place 11-13 December in Geneva, Switzerland. Presentation details: Abstracts will be made available on ...
Yahoo Finance16d
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024 taking place 11-13 December in Geneva, Switzerland. Abstracts will be made available on the ESMO I-O website ...
BioSpace9dOpinion
Opinion: Ten Years After Keytruda’s Seminal Approval, Immuno-oncology Is Poised for the Next Revolution
While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...
News Medical9d
Oncology News and Research
A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA and ...
pharmaphorum2d
ESMO: GSK, iTeos bring some optimism back to TIGIT
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...
Cambridge University Press29d
In-person prospective audit and feedback on an oncology ward: development of an immunocompromised antimicrobial stewardship program
MI, USA We reviewed all patients receiving antimicrobials on inpatient oncology services who were included in IPPAF and prospectively documented clinical syndromes represented, most common ...
pharmaphorum1d
Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal
Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The Dublin-based pharma ...
Seeking Alpha28d
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable?
Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...
Stockhouse15d
Immutep Quarterly Activities Report Q1 FY25
In July, Immutep reported updated positive efficacy and safety results from Cohort B of the TACTI-003 Phase IIb trial at an ESMO Virtual Plenary session ... chemotherapy in patients with CPS <1. The ...
Yahoo Finance8d
Taiho Oncology to Present Data at the 66th American Society of Hematology Annual Meeting
"These data add to the body of evidence for Taiho Oncology's expanding hematology portfolio and demonstrate our continued commitment to bring innovative therapies to patients with cancer." ...